

Astellas APAC GU Masterclass

XTANDI[®] (enzalutamide)

Conrad Seoul, Seoul, Republic of Korea

Friday, July 11, 2025, 18:30–20:15 KST

Saturday, July 12, 2025, 08:30–16:45 KST

Astellas Pharma Korea, Inc.
7F, Parnas Tower, 521 Teheran-ro, Gangnam-gu,
Seoul, Republic of Korea



XTANDI soft capsule 40 mg
(enzalutamide)

Disclaimers

- This masterclass is fully sponsored and organized by Astellas. Speakers have received honoraria for the production of materials, and this meeting may include promotional messages related to Astellas products
- This masterclass is intended for HCPs only
- The statements provided in this masterclass include the views and opinions of the presenters. Where possible, claims made in this presentation have been reviewed by medical and legal representatives of Astellas
- The information, views and opinions presented herein are those of the presenter, and the presenter is solely responsible for the materials being introduced in this presentation. Although patients' cases mentioned herein are actual cases, it may differ from local approval product information. Such information, views and opinions of the presenter do not necessarily reflect the information, views and opinions of Astellas. Astellas does not recommend the use of any product in any different manner than as described in the local approval information, and complies with all applicable laws, regulations, and company policies.
- This presentation may contain copyrighted material and should not be copied or distributed
- To report an adverse event, please contact safety.kr@kr.astellas.com

Welcome and introduction

Prof. Inkeun Park (Chair)

Disclosures

Prof. Inkeun Park (Chair)

- **Grant/research support:** Amgen, Astellas, Boryung, Chong Kun Dang
- **Consulting or advisory role:** Astellas, AstraZeneca, Bayer, BMS, Celltrion, Chong Kun Dang, Ipsen, Janssen, Merck, MSD, Novartis, ONO

Day 2: Prostate Cancer Masterclass meeting objectives



Emphasize the importance of optimal treatment choice, with a focus on 1L systemic treatment choice in prostate cancer, as part of the pathway of care

Understand expert opinion treatment choices in mHSPC

Provide expert advice on optimizing QoL with a holistic care approach and focus on AE management

Faculty




Chair: Prof. Inkeun Park
South Korea



Prof. Çağatay Arslan
Türkiye



Prof. Lisa Horvath
Australia



Dr Po-Hung Lin
Taiwan




Prof. Chang Gon Kim
South Korea

Day 2: Agenda

Duration (KST)	Session	Speaker(s)
14:00–14:05	Welcome and introduction	Prof. Inkeun Park (Chair) (KR)
14:05–14:40	The evolving role of ARPIs in mHSPC	Prof. Çağatay Arslan (Türkiye)
14:40–15:25	Management of patients with advanced prostate cancer: The latest APCCC recommendations	Prof. Lisa Horvath (Australia)
15:25–15:35	<i>Coffee break</i>	
15:35–16:35	Putting patients at the center: Case studies	Dr Po-Hung Lin (TW) Prof. Chang Gon Kim (KR)
16:35–16:45	Take-home messages and meeting close	Prof. Inkeun Park (Chair) (KR)


Housekeeping



Please put your electronic devices on silent mode



Submit your questions throughout the meeting via the Onomi app



Please note this meeting is being recorded and livestreamed online

How to submit questions/use polls

Please scan the QR code on your mobile device to submit questions and respond to polls

- When downloaded, please open the Onomi app
- Tap on “Get Started”
- Next, tap on “Email me a magic link” and check your inbox. You will receive a six-digit code, which you will need to input into your device
- You will then need to agree to the GDPR and Terms and Conditions before the app can begin to download content to your device



We want to hear your opinions during polling questions and the Q&A session!

Test poll: Question for the audience

- In which year did South Korea host the summer Olympic games in Seoul?

A 1975

B 1988

C 1999

D 2005

E 2014

Test poll: Question for the audience

- In which year did South Korea host the summer Olympic games in Seoul?

A 1975

B 1988

C 1999

D 2005

E 2014